23J0 Stock Overview

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. More details

23J0 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 53.1% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

+ 3 more risks

My Notes

Capture your thoughts, links and company narrative

ProMIS Neurosciences, Inc. Competitors

Medigene

XTRA:MDG1

€18.9m

4SC

DB:VSC

€58.9m

2invest

XTRA:2INV

€67.3m

Heidelberg Pharma

XTRA:HPHA

€116.0m

Price History & Performance

Summary of share price highs, lows and changes for ProMIS Neurosciences
Historical stock prices
Current Share Price	US$0.88
52 Week High	US$2.16
52 Week Low	US$0.76
Beta	0.55
1 Month Change	2.94%
3 Month Change	15.13%
1 Year Change	-53.70%
3 Year Change	-84.65%
5 Year Change	-88.95%
Change since IPO	-85.70%

Recent updates

Shareholder Returns

	23J0	DE Biotechs	DE Market
7D	-11.6%	-1.9%	3.5%
1Y	-53.7%	-4.2%	13.1%

Return vs Industry: 23J0 underperformed the German Biotechs industry which returned -3.8% over the past year.

Return vs Market: 23J0 underperformed the German Market which returned 12.8% over the past year.

Price Volatility

Is 23J0's price volatile compared to industry and market?
23J0 volatility
23J0 Average Weekly Movement	12.2%
Biotechs Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 23J0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 23J0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2004	7	Neil K. Warma	www.promisneurosciences.com

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.

ProMIS Neurosciences, Inc. Fundamentals Summary

How do ProMIS Neurosciences's earnings and revenue compare to its market cap?
23J0 fundamental statistics
Market cap	€27.98m
Earnings (TTM)	-€541.72k
Revenue (TTM)	n/a

0.0x

P/S Ratio

-51.6x

P/E Ratio

Is 23J0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
23J0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$8.54m
Gross Profit	-US$8.54m
Other Expenses	-US$7.98m
Earnings	-US$563.35k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.017
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 23J0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/20 20:33
End of Day Share Price	2025/01/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ProMIS Neurosciences, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Thomas Shrader	BTIG
Eddie Hickman	Guggenheim Securities, LLC
Douglas Loe	Leede Jones Gable Inc

23J0 Stock Overview

Risk Analysis

ProMIS Neurosciences, Inc. Competitors

XTRA:MDG1

€18.9m

DB:VSC

€58.9m

XTRA:2INV

€67.3m

XTRA:HPHA

€116.0m

Price History & Performance

Recent News & Updates

ProMIS Neurosciences Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price Rule

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

Recent updates

ProMIS Neurosciences Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price Rule

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

No longer forecast to breakeven

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

Revenue in line with expectations

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

First half earnings released